Hermeling S - Search Results

1

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W. Hermeling S, et al. Pharm Res. 2005 Dec;22(12):1997-2006. doi: 10.1007/s11095-005-8177-9. Epub 2005 Oct 3. Pharm Res. 2005. PMID: 16184451

2

Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?

Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Hermeling S, et al. Pharm Res. 2003 Dec;20(12):1903-7. doi: 10.1023/b:pham.0000008034.61317.02. Pharm Res. 2003. PMID: 14725351

3

Structure-immunogenicity relationships of therapeutic proteins.

Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Hermeling S, et al. Pharm Res. 2004 Jun;21(6):897-903. doi: 10.1023/b:pham.0000029275.41323.a6. Pharm Res. 2004. PMID: 15212151 Review.

4

Development of a transgenic mouse model immune tolerant for human interferon Beta.

Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Hermeling S, et al. Pharm Res. 2005 Jun;22(6):847-51. doi: 10.1007/s11095-005-4578-z. Epub 2005 Jun 8. Pharm Res. 2005. PMID: 15948027

5

Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.

Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Hermeling S, et al. J Pharm Sci. 2006 May;95(5):1084-96. doi: 10.1002/jps.20599. J Pharm Sci. 2006. PMID: 16552750

6

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W. van Beers MM, et al. Among authors: hermeling s. J Immunol Methods. 2010 Jan 31;352(1-2):32-7. doi: 10.1016/j.jim.2009.10.005. Epub 2009 Oct 24. J Immunol Methods. 2010. PMID: 19857496

7

A role for protein misfolding in immunogenicity of biopharmaceuticals.

Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF. Maas C, et al. Among authors: hermeling s. J Biol Chem. 2007 Jan 26;282(4):2229-36. doi: 10.1074/jbc.M605984200. Epub 2006 Nov 29. J Biol Chem. 2007. PMID: 17135263 Free article.

8

Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.

Hermeling S, Jiskoot W, Crommelin DJ, Schellekens H. Hermeling S, et al. Pharm Res. 2006 Mar;23(3):641-2; author reply 643-4. doi: 10.1007/s11095-006-9573-5. Epub 2006 Mar 15. Pharm Res. 2006. PMID: 16525860

9

Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system.

Killian DM, Hermeling S, Chikhale PJ. Killian DM, et al. Among authors: hermeling s. Drug Deliv. 2007 Jan;14(1):25-31. doi: 10.1080/10717540600559510. Drug Deliv. 2007. PMID: 17107928 Free article.

10

Gut microbiota prevents small intestinal tumor formation due to bile acids in gnotobiotic mice.

Wortmann E, Wylensek D, Basic M, Hermeling S, Bleich A, Haller D, Tolba R, Liebisch G, Janssen KP, Clavel T. Wortmann E, et al. Among authors: hermeling s. Microbiome Res Rep. 2024 Aug 29;3(4):44. doi: 10.20517/mrr.2024.20. eCollection 2024. Microbiome Res Rep. 2024. PMID: 39741948 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters